PA
ALDX icon

Parallel Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Parallel Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30
Closed -$173 – 3540
2025
Q1 		$173 Buy
+30
New +$177 ﹤0.01% 3402
2021
Q4 		– Sell
-17
Closed – – 3055
2021
Q3 		$0 Buy
+17
New +$156 ﹤0.01% 3051

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's ALDX Position: Q2 2025 in Review

Parallel Advisors sold out of Aldeyra Therapeutics (ALDX) in Q2 2025, closing a stake of 30 shares — an estimated $173 sold.

Parallel Advisors first reported a position in ALDX in Q3 2021 and held it in 2 quarters. The position peaked at $173 in Q1 2025. 121 funds tracked by Wall St. Rank hold ALDX as of Q2 2025.

  • Parallel Advisors reported no remaining Aldeyra Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Parallel Advisors sold 30 Aldeyra Therapeutics shares in Q2 2025, an estimated $173.
  • Parallel Advisors first reported a position in Aldeyra Therapeutics in Q3 2021 and held it in 2 quarters.
  • Parallel Advisors's Aldeyra Therapeutics position peaked at $173 in Q1 2025.
  • 121 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2025.

Based on Parallel Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.